Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26502997 | 0.86 | NPSR1 (0.38) | NPSR1RXRAL3MBTL1KDM4ENPC1 | |
| SCHEMBL26117252 | 0.82 | HCAR3 (0.41) | NPSR1RXRAKDM4EHPGD | |
| SCHEMBL29462127 | 0.82 | HCAR3 (0.41) | NPSR1RXRAKDM4EHPGD | |
| SCHEMBL29462128 | 0.82 | HCAR3 (0.50) | RXRAHPGD | |
| SCHEMBL26114008 | 0.82 | HCAR3 (0.50) | RXRAHPGD | |
| SCHEMBL29462123 | 0.82 | HCAR3 (0.50) | RXRAHPGD | |
| SCHEMBL26503099 | 0.82 | ALDH1A1 (0.44) | NPSR1RXRAHPGDALDH1A1 | |
| SCHEMBL2067352 | 0.64 | MAPT (0.59) | L3MBTL1KDM4ENPC1HPGDALDH1A1 | |
| SCHEMBL16082293 | 0.64 | LMNA (0.56) | ALDH1A1GAA | |
| SCHEMBL22548327 | 0.64 | ALDH1A1 (0.45) | KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322688-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322688-A1 | THERAPEUTIC COMPOUNDS | IL5, IL15, IL4 | NPSR1 181/4885RXRA 1242/4885L3MBTL1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.